Skip to main content

Licensing of pharmaceutical representatives (SB 763) RAC

The Department of Consumer and Business Services (DCBS) is preparing to begin rulemaking on the licensing of pharmaceutical representatives specifically for SB 763 enacted during the 2021 Legislative Session. This bill provides that a person may not engage in business as pharmaceutical representative without obtaining a license from the director of DCBS.

Temporary Rules for Pharmaceutical Sales Representative Licensing.

All meetings held via Microsoft Teams meetings.
Join on your computer or mobile app.*
*Download the Microsoft Teams app

Committee Contacts:

Numi Lee Griffith
Senior Policy Adviser
Division of Financial Regulation
Numi.L.Griffith@dcbs.oregon.gov
Phone: 503-428-4723

Karen Winkel
Rules Coordinator
Division of Financial Regulation
Karen.J.Winkel@dcbs.oregon.gov
Phone: 503-947-7694


Scheduled meetings:

Tues. March 1, 2022


Comments:

​​​​​​​10/11/2021
Sherry Dismukes
Novartis

10/18/2021
​​ Maribeth Guarino
OSPIRG

10/18/21
PhRMA

10/19/21
Becker, Blackwell

OCAP, PacificSource

10/19/21
Boehringer, Ingelheim

10/19/21
Anne Murray

Bristol Myers Squibb

10/19/21
Brian Van Hoy

G&M Health

11/9/21
Becker, Guarino, Blackwell
OCAP, OSPIRG, PacificSource

11/9/21
PhRMA

1/28/22
Brian Van Hoy
G&M Health

2/1/22
Anne Murray
Bristol Myers Squibb

2/1/22
PhRMA

3/11/22
Brian ​Van Hoy

G&M Health

3/17/22
PhRMA


Committee:

Anne Murray
Bristol-Myers-Squibb

Asher Lisec
PhRMA

Brian Van Hoy
G&M Health, LLC

Chloe Becker
OCAP

Jen Baker
Providence

Maribeth Guarino
OSPIRG

Mark Bonanno
Oregon Medical Association

Rick Blackwell
PacificSource

Public Meetings:

Advisory committee meetings are open to the public. Public comments are allowed at the end of each RAC meeting. Due to time limitations and to ensure that public comments are correctly recorded, individuals are strongly encouraged to submit public comments in writing via email to DFR.rules@dcbs.oregon.gov